Liquid Biopsy and Primary Brain Tumors
Two decades of “promising results” in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises, developmen...
Saved in:
Main Authors: | , |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/15b06a90d565445fb3053b7063943985 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:doaj.org-article:15b06a90d565445fb3053b7063943985 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:15b06a90d565445fb3053b70639439852021-11-11T15:31:21ZLiquid Biopsy and Primary Brain Tumors10.3390/cancers132154292072-6694https://doaj.org/article/15b06a90d565445fb3053b70639439852021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5429https://doaj.org/toc/2072-6694Two decades of “promising results” in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises, developments, and challenges related to liquid biopsy of brain tumors, including circulating tumor cells, cell-free nucleic acids, extracellular vesicles, and miRNA; we further discuss the urgent need to establish suitable biomarkers and the right standards to improve modern clinical management of brain tumor patients with the use of liquid biopsy.Robert H. EiblMarkus SchneemannMDPI AGarticleliquid biopsybrain tumorglioblastomagliomamedulloblastomacirculating tumor cell—CTCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5429, p 5429 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
liquid biopsy brain tumor glioblastoma glioma medulloblastoma circulating tumor cell—CTC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
liquid biopsy brain tumor glioblastoma glioma medulloblastoma circulating tumor cell—CTC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Robert H. Eibl Markus Schneemann Liquid Biopsy and Primary Brain Tumors |
description |
Two decades of “promising results” in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises, developments, and challenges related to liquid biopsy of brain tumors, including circulating tumor cells, cell-free nucleic acids, extracellular vesicles, and miRNA; we further discuss the urgent need to establish suitable biomarkers and the right standards to improve modern clinical management of brain tumor patients with the use of liquid biopsy. |
format |
article |
author |
Robert H. Eibl Markus Schneemann |
author_facet |
Robert H. Eibl Markus Schneemann |
author_sort |
Robert H. Eibl |
title |
Liquid Biopsy and Primary Brain Tumors |
title_short |
Liquid Biopsy and Primary Brain Tumors |
title_full |
Liquid Biopsy and Primary Brain Tumors |
title_fullStr |
Liquid Biopsy and Primary Brain Tumors |
title_full_unstemmed |
Liquid Biopsy and Primary Brain Tumors |
title_sort |
liquid biopsy and primary brain tumors |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/15b06a90d565445fb3053b7063943985 |
work_keys_str_mv |
AT robertheibl liquidbiopsyandprimarybraintumors AT markusschneemann liquidbiopsyandprimarybraintumors |
_version_ |
1718435225404440576 |